Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative chemoradiotherapy for potentially resectable adenocarcinoma of the esophagogastric junction
ChiCTR-TRC-12002393Phase 2Completed
- Sponsor
- The Fourth Hospital of Hebei Medical University
- Start
- Sep 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of capecitabine and oxaliplatin in Esophago-Gastric Adenocarcinoma (2 arms), sponsored by The Fourth Hospital of Hebei Medical University. Primary endpoint: 3-year disease-free survival. Started Sep 2012; status: completed.
02
Drugs
capecitabineoxaliplatin
03
Conditions
Esophago-Gastric Adenocarcinoma
Beyond the preview
Go deeper on ChiCTR-TRC-12002393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-12002393.